Ubs Asset Management Americas Inc Gilead Sciences, Inc. Transaction History
Ubs Asset Management Americas Inc
- $417 Billion
- Q4 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 12,234,672 shares of GILD stock, worth $1.37 Billion. This represents 0.27% of its overall portfolio holdings.
Number of Shares
12,234,672
Previous 10,628,942
15.11%
Holding current value
$1.37 Billion
Previous $891 Million
26.85%
% of portfolio
0.27%
Previous 0.23%
Shares
29 transactions
Others Institutions Holding GILD
# of Institutions
2,094Shares Held
1.02BCall Options Held
8.73MPut Options Held
9.63M-
Black Rock Inc. New York, NY121MShares$13.5 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA116MShares$12.9 Billion0.19% of portfolio
-
Capital World Investors Los Angeles, CA71.7MShares$8.03 Billion1.05% of portfolio
-
State Street Corp Boston, MA60.4MShares$6.76 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA57.9MShares$6.49 Billion1.15% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $140B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...